Table 2.

Hazard Ratios (HRs) of Study End Points for Plasma Levels of Interleukin 6 (IL-6), High-Sensitivity C-Reactive Protein (hsCRP), and D-Dimer

End Point	IL-6, HR (95% CI)		hsCRP, HR (95% CI)		D-Dimer, HR (95% CI)
	2-Fold Higher Level	4th/1st Quartile	2-Fold Higher Level	4th/1st Quartile	2-Fold Higher Level	4th/1st Quartile
All-cause death	1.64 (1.41–1.92)	3.07 (1.70–5.55)	1.29 (1.17–1.42)	2.73 (1.56–4.69)	1.32 (1.14–1.52)	3.00 (1.61–5.59)
Non–AIDS-related, nonviolent, unintentional death	1.77 (1.50–2.10)	6.31 (2.68–14.83)	1.30 (1.16–1.46)	3.10 (1.59–6.05)	1.30 (1.10–1.53)	3.38 (1.62–7.08)
Progression to AIDS	1.32 (1.07–1.62)	1.63 (.83–3.21)	1.07 (.94–1.21)	1.35 (.74–2.48)	1.35 (1.12–1.63)	2.20 (1.07–4.50)
Cardiovascular disease event	1.40 (1.17–1.67)	3.34 (1.66–6.70)	1.11 (.99–1.24)	1.89 (.99–3.63)	1.22 (1.04–1.43)	1.80 (.98–3.29)
Non–AIDS-defining malignancy	1.31 (1.07–1.61)	3.12 (1.42–6.84)	1.16 (1.02–1.32)	1.68 (.86–3.28)	1.09 (.91–1.31)	1.03 (.55–1.94)

HRs were adjusted for demographic characteristics (age, sex, race, and body mass index [calculated as the weight in kilograms divided by the height in meters squared]), nadir and baseline CD4⁺ T-cell counts, antiretroviral therapy use, baseline human immunodeficiency virus RNA level, prior AIDS and cardiovascular disease, diabetes mellitus, and hepatitis B virus and hepatitis C virus coinfection, stratified by study (model 2). For detailed information on results using models 1 and 3, refer to Supplementary Tables 1 and 2.

Abbreviation: CI, confidence interval.